Printer Friendly

VESTAR FILES PATENT INFRINGEMENT LAWSUIT IN UNITED KINGDOM AGAINST LIPOSOME TECHNOLOGY, INC.

 SAN DIMAS, Calif., March 1 /PRNewswire/ -- Vestar, Inc. (NASDAQ: VSTR) today announced that it has filed a patent infringement lawsuit against Liposome Technology, Inc. of Menlo Park, Calif. The lawsuit, filed in the Patents County Court in the United Kingdom, alleges that Doxil, Liposome Technology's investigational anticancer product, infringes Vestar's European Patent (U.K.) No. 0179444 on tumor targeting.
 Vestar's patent covers the targeting to tumors of liposomes containing chemotherapeutic agents. Doxil contains the anticancer agent doxorubicin, and is currently undergoing clinical trials.
 Vestar, headquartered in San Dimas, Calif., develops, manufactures and markets pharmaceuticals to treat patients with cancer and serious infections, including AIDS. Since 1989, Vestar has been marketing in Europe AmBisome(R), a liposomal formulation of amphotericin B, to treat systemic fungal infections. DaunoXome(R), a liposomal formulation of the chemotherapeutic agent daunorubicin, is Vestar's second major product, for which a New Drug Application was filed with the FDA in February 1993. Among the company's proprietary drug delivery technologies are liposomes to encapsulate pharmaceuticals, and lipid prodrug technology for the development of orally active compounds.
 -0- 3/1/93
 /CONTACT: Michael E. Hart, chief financial officer, Vestar, Inc. 909-394-4119; Marcia A. Kean, executive vice president, Feinstein Partners, Inc., 617-577-8110/
 (VSTR)


CO: Vestar, Inc. ST: California IN: MTC SU:

DJ -- NE009 -- 1394 03/01/93 11:54 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 1, 1993
Words:219
Previous Article:SWIFT TRANSPORTATION CO. INC. ANNOUNCES SLOWDOWN IN FIRST QUARTER REVENUES
Next Article:BITSTREAM ROLLS OUT NEW NOVELTY FONT PACKS FOR WINDOWS 3.1, LAUNCHES FIRST LI'L BITS FONT PACKS FOR THE MACINTOSH
Topics:


Related Articles
VESTAR FILES COUNTERCLAIM VS. THE LIPOSOME COMPANY: ALLEGES THAT PATENT IS INVALID AND DENIES INFRINGEMENT
THE LIPOSOME COMPANY SUES VESTAR; SUIT CHARGES VESTAR'S AMBISOME INFRINGES LIPOSOME'S PATENT
VESTAR TO REVIEW LEGAL DOCUMENTS; BELIEVES PATENTS ARE SECURE
VESTAR EXPRESSES CONFIDENCE IN PATENT POSITION; WILL VIGOROUSLY CONTEST ALL INFRINGEMENT ALLEGATIONS
VESTAR FILES SUIT AGAINST LIPOSOME TECHNOLOGY, INC.
LIPOSOME TECHNOLOGY, INC. ANNOUNCES JUDGMENT
VESTAR, INC. AND LIPOSOME TECHNOLOGY, INC. SETTLE EUROPEAN PATENT LITIGATION
Osteotech Announces Development in Lawsuit Against GenSci.
Incyte licenses comprehensive microarray patent portfolio to Chiron.
MorphoSys confirms filing of new patent lawsuit by CAT.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters